Progen Co. Ltd.
KKRX:2961602,045.00
KRW
0.00
(0.00%)
ISIN
KR7296160005
Return %
Stock
S&P 500
1Y
-66.42
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jong-Kyun Kim
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Seoul South Korea
- IPO Date
- Nov 15, 2023
- Website
- progen.co.kr
- Similar Companies
- Business
- Progen Co., Ltd. is a clinical-stage biopharmaceutical company that specializes in the research, discovery, and development of next-generation, long-acting, and multi-specific biologic therapeutics for metabolic disorders, oncology, and immune-mediated diseases. The company operates through advanced biopharmaceutical research and proprietary platform technology segments, focusing on engineered fusion proteins and bio-better drug candidates. Progen's product and technology portfolio includes the proprietary NTIG (Neo Tri-ImmunoGlobulin) platform, a protein engineering technology designed to extend in vivo half-life, enhance pharmacokinetic stability, and enable multi-target bispecific fusion binding; PG-102, a first-in-class, long-acting GLP-1/GLP-2 dual receptor agonist candidate engineered for the treatment of obesity and type 2 diabetes; RT-114 (RPG-102), an oral formulation of PG-102 developed in conjunction with robotic capsule delivery mechanisms for once-weekly oral administration in metabolic indications; PG-101, a therapeutic biologic candidate evaluated for metastatic castration-resistant prostate cancer; and exploratory multi-specific biologic assets including the PG-200 and PG-400 series directed at immuno-oncology, inflammatory, and autoimmune disease targets. The company serves the global pharmaceutical and healthcare sectors, engaging with clinical development partners, biotechnology licensors, and medical research institutions across South Korea, the United States, Australia, and international markets. In recent corporate developments, South Korea-based Yuhan Corporation became Progen's largest shareholder through a strategic equity investment of approximately 30 billion KRW (approximately 23 million USD), establishing a comprehensive collaborative R&D alliance and joint drug development committee to co-develop next-generation biologics and immuno-oncology bispecific antibodies. Furthermore, Progen established an international strategic partnership with United States-based Rani Therapeutics to co-develop and commercialize RT-114, integrating PG-102 with the RaniPill oral delivery capsule platform and progressing the program into clinical trials. Progen has also expanded its global clinical footprint by advancing injectable PG-102 into multi-regional Phase 2 clinical trials, evaluating its metabolic efficacy, body composition improvements, and gastrointestinal tolerability in head-to-head assessments against benchmark GLP-1 therapies. Founded in 1998, Progen Co., Ltd. is headquartered in Seoul, South Korea, and is listed on the Korea New Exchange (KONEX: 296160) while operating as a strategic biopharmaceutical affiliate of Yuhan Corporation.